Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues FY24 Earnings Guidance

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $19.50-20.60 for the period, compared to the consensus earnings per share estimate of $19.51. The company issued revenue guidance of $4.0-4.1 billion, compared to the consensus revenue estimate of […]

Leave a Reply

Your email address will not be published.

Previous post ARM (NASDAQ:ARM) Releases Q3 Earnings Guidance
Next post Hologic (NASDAQ:HOLX) Announces Approval of Performance Stock Unit Award Agreements for Fiscal 2025